When symptoms persist: Clozapine augmentation strategies

Peter F Buckley, Alexander Miller, Jerry Olsen, David Garver, Del D. Miller, John Csernansky

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Recent data and clinical experience confirm that, in spite of superior efficacy for treatment-refractory schizophrenia, a substantial proportion of patients receiving clozapine will continue to experience disabling symptoms. Optimizing clozapine monotherapy is the first step in the management of "clozapine non-responders." Described here is a synthesis of the available literature on the range and efficacy of clozapine augmentation strategies that may be used when monotherapy fails. Treatment options include adjunctive antipsychotic medications, mood stabilizers, selective serotonin reuptake inhibitors, glycinergic agents, and electroconvulsive therapy. The evidence favoring one augmentation strategy over another is lacking; overall, adjunctive therapy is associated with only modest clinical improvement. Moreover, case series and open-labeled clinical trials dominate the extant literature, and there is a dearth of double-blind trials comparing these augmentation agents. Current systematic efforts to enhance the treatment of these patients with adjunctive therapies are worthy of being studied in carefully conducted clinical trials.

Original languageEnglish (US)
Pages (from-to)615-628
Number of pages14
JournalSchizophrenia Bulletin
Volume27
Issue number4
DOIs
StatePublished - Jan 1 2001

Fingerprint

Clozapine
Glycine Agents
Clinical Trials
Electroconvulsive Therapy
Serotonin Uptake Inhibitors
Therapeutics
Antipsychotic Agents
Schizophrenia

Keywords

  • Antipsychotic response
  • Augmentation
  • Clozapine
  • Schizophrenia
  • Treatment refractory

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Buckley, P. F., Miller, A., Olsen, J., Garver, D., Miller, D. D., & Csernansky, J. (2001). When symptoms persist: Clozapine augmentation strategies. Schizophrenia Bulletin, 27(4), 615-628. https://doi.org/10.1093/oxfordjournals.schbul.a006901

When symptoms persist : Clozapine augmentation strategies. / Buckley, Peter F; Miller, Alexander; Olsen, Jerry; Garver, David; Miller, Del D.; Csernansky, John.

In: Schizophrenia Bulletin, Vol. 27, No. 4, 01.01.2001, p. 615-628.

Research output: Contribution to journalArticle

Buckley, PF, Miller, A, Olsen, J, Garver, D, Miller, DD & Csernansky, J 2001, 'When symptoms persist: Clozapine augmentation strategies', Schizophrenia Bulletin, vol. 27, no. 4, pp. 615-628. https://doi.org/10.1093/oxfordjournals.schbul.a006901
Buckley PF, Miller A, Olsen J, Garver D, Miller DD, Csernansky J. When symptoms persist: Clozapine augmentation strategies. Schizophrenia Bulletin. 2001 Jan 1;27(4):615-628. https://doi.org/10.1093/oxfordjournals.schbul.a006901
Buckley, Peter F ; Miller, Alexander ; Olsen, Jerry ; Garver, David ; Miller, Del D. ; Csernansky, John. / When symptoms persist : Clozapine augmentation strategies. In: Schizophrenia Bulletin. 2001 ; Vol. 27, No. 4. pp. 615-628.
@article{06517dfb282f48bc89da4581e6eb8bb2,
title = "When symptoms persist: Clozapine augmentation strategies",
abstract = "Recent data and clinical experience confirm that, in spite of superior efficacy for treatment-refractory schizophrenia, a substantial proportion of patients receiving clozapine will continue to experience disabling symptoms. Optimizing clozapine monotherapy is the first step in the management of {"}clozapine non-responders.{"} Described here is a synthesis of the available literature on the range and efficacy of clozapine augmentation strategies that may be used when monotherapy fails. Treatment options include adjunctive antipsychotic medications, mood stabilizers, selective serotonin reuptake inhibitors, glycinergic agents, and electroconvulsive therapy. The evidence favoring one augmentation strategy over another is lacking; overall, adjunctive therapy is associated with only modest clinical improvement. Moreover, case series and open-labeled clinical trials dominate the extant literature, and there is a dearth of double-blind trials comparing these augmentation agents. Current systematic efforts to enhance the treatment of these patients with adjunctive therapies are worthy of being studied in carefully conducted clinical trials.",
keywords = "Antipsychotic response, Augmentation, Clozapine, Schizophrenia, Treatment refractory",
author = "Buckley, {Peter F} and Alexander Miller and Jerry Olsen and David Garver and Miller, {Del D.} and John Csernansky",
year = "2001",
month = "1",
day = "1",
doi = "10.1093/oxfordjournals.schbul.a006901",
language = "English (US)",
volume = "27",
pages = "615--628",
journal = "Schizophrenia Bulletin",
issn = "0586-7614",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - When symptoms persist

T2 - Clozapine augmentation strategies

AU - Buckley, Peter F

AU - Miller, Alexander

AU - Olsen, Jerry

AU - Garver, David

AU - Miller, Del D.

AU - Csernansky, John

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Recent data and clinical experience confirm that, in spite of superior efficacy for treatment-refractory schizophrenia, a substantial proportion of patients receiving clozapine will continue to experience disabling symptoms. Optimizing clozapine monotherapy is the first step in the management of "clozapine non-responders." Described here is a synthesis of the available literature on the range and efficacy of clozapine augmentation strategies that may be used when monotherapy fails. Treatment options include adjunctive antipsychotic medications, mood stabilizers, selective serotonin reuptake inhibitors, glycinergic agents, and electroconvulsive therapy. The evidence favoring one augmentation strategy over another is lacking; overall, adjunctive therapy is associated with only modest clinical improvement. Moreover, case series and open-labeled clinical trials dominate the extant literature, and there is a dearth of double-blind trials comparing these augmentation agents. Current systematic efforts to enhance the treatment of these patients with adjunctive therapies are worthy of being studied in carefully conducted clinical trials.

AB - Recent data and clinical experience confirm that, in spite of superior efficacy for treatment-refractory schizophrenia, a substantial proportion of patients receiving clozapine will continue to experience disabling symptoms. Optimizing clozapine monotherapy is the first step in the management of "clozapine non-responders." Described here is a synthesis of the available literature on the range and efficacy of clozapine augmentation strategies that may be used when monotherapy fails. Treatment options include adjunctive antipsychotic medications, mood stabilizers, selective serotonin reuptake inhibitors, glycinergic agents, and electroconvulsive therapy. The evidence favoring one augmentation strategy over another is lacking; overall, adjunctive therapy is associated with only modest clinical improvement. Moreover, case series and open-labeled clinical trials dominate the extant literature, and there is a dearth of double-blind trials comparing these augmentation agents. Current systematic efforts to enhance the treatment of these patients with adjunctive therapies are worthy of being studied in carefully conducted clinical trials.

KW - Antipsychotic response

KW - Augmentation

KW - Clozapine

KW - Schizophrenia

KW - Treatment refractory

UR - http://www.scopus.com/inward/record.url?scp=0035697271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035697271&partnerID=8YFLogxK

U2 - 10.1093/oxfordjournals.schbul.a006901

DO - 10.1093/oxfordjournals.schbul.a006901

M3 - Article

C2 - 11824488

AN - SCOPUS:0035697271

VL - 27

SP - 615

EP - 628

JO - Schizophrenia Bulletin

JF - Schizophrenia Bulletin

SN - 0586-7614

IS - 4

ER -